2023
P-034 Alnuctamab (ALNUC; BMS-986349; CC-93269), a BCMA × CD3 T-cell engager, in patients (pts) with relapsed/refractory multiple myeloma (RRMM): latest results from a phase 1 first-in-human clinical study
Costa L, Bar N, Mateos M, Ribas P, Hansson M, Paris L, Hofmeister C, Rodriguez-Otero P, Bermúdez M, Santoro A, Yee A, Creignou M, Encinas C, Cerchione C, de la Rubia J, Oriol A, Ferstl B, Besemer B, Chen J, Boss I, Gaudy A, Hsu K, Godwin C, San-Miguel J, Wong S. P-034 Alnuctamab (ALNUC; BMS-986349; CC-93269), a BCMA × CD3 T-cell engager, in patients (pts) with relapsed/refractory multiple myeloma (RRMM): latest results from a phase 1 first-in-human clinical study. Clinical Lymphoma Myeloma & Leukemia 2023, 23: s52-s53. DOI: 10.1016/s2152-2650(23)01652-x.Peer-Reviewed Original ResearchP883: ALNUCTAMAB (ALNUC; BMS‐986349; CC‐93269), A BCMA × CD3 T‐CELL ENGAGER, IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): LATEST RESULTS FROM A PHASE 1 FIRST‐IN‐HUMAN CLINICAL STUDY
Wong S, Bar N, Victoria Mateos M, Ribas P, Hansson M, Paris L, Hofmeister C, Rodriguez-Otero P, Aranzazu Bermúdez M, Santoro A, Yee A, Creignou M, Encinas C, Cerchione C, de la Rubia J, Oriol A, Ferstl B, Besemer B, Chen J, Chung A, Boss I, Gaudy A, LI S, Hsu K, Godwin C, Burgess M, San-Miguel J, Jose Costa L. P883: ALNUCTAMAB (ALNUC; BMS‐986349; CC‐93269), A BCMA × CD3 T‐CELL ENGAGER, IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): LATEST RESULTS FROM A PHASE 1 FIRST‐IN‐HUMAN CLINICAL STUDY. HemaSphere 2023, 7: e1220745. PMCID: PMC10431068, DOI: 10.1097/01.hs9.0000970436.12207.45.Peer-Reviewed Original Research
2022
Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-Cell Maturation Antigen (BCMA) x CD3 T-Cell Engager (TCE), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from a Phase 1 First-in-Human Clinical Study
Wong S, Bar N, Paris L, Hofmeister C, Hansson M, Santoro A, Mateos M, Rodríguez-Otero P, Lund J, Encinas C, Yee A, Oriol A, Cerchione C, de la Rubia J, Ferstl B, Carlson K, Ribas P, Bermúdez A, Boss I, Gaudy A, Li S, Hsu K, Godwin C, Burgess M, San-Miguel J, Costa L. Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-Cell Maturation Antigen (BCMA) x CD3 T-Cell Engager (TCE), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from a Phase 1 First-in-Human Clinical Study. Blood 2022, 140: 400-402. DOI: 10.1182/blood-2022-159009.Peer-Reviewed Original Research